Liquidia Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference: A Promising Biopharma Stock

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company focused on developing innovative therapies for rare cardiopulmonary diseases, has announced that its CEO, Dr. Roger Jeffs, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time (12:45 p.m. Eastern Time) at the Westin St. Francis in San Francisco, California. The event will feature a live, audio-only webcast accessible via the "Investors" page on Liquidia's website at .

Liquidia's presentation at the J.P. Morgan Healthcare Conference is an excellent opportunity for investors to learn more about the company's recent developments, financial performance, and future growth prospects. The conference is the largest and most informative healthcare investment symposium in the industry, connecting global industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.


Table showing Liquidia's financial performance for the past three years:
| Year | Revenue (in $ million) | Net Income (in $ million) |
| --- | --- | --- |
| 2021 | 12.85 | -0.70 |
| 2022 | 15.94 | -0.67 |
| 2023 | 17.49 | -1.21 |


Liquidia's financial performance has shown steady growth over the past three years, with revenue increasing from $12.85 million in 2021 to $17.49 million in 2023. The company has also made significant progress in its product pipeline, with its lead product candidate, YUTREPIA, receiving tentative approval from the FDA for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). YUTREPIA is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep lung delivery and achieving higher dose levels than current inhaled therapies.

"YUTREPIA Inhaler"

Liquidia's presentation at the J.P. Morgan Healthcare Conference is expected to provide valuable insights into the company's plans for YUTREPIA's commercialization, as well as updates on its other product candidates and collaborations. The conference is an ideal platform for Liquidia to showcase its innovative therapies and connect with potential investors, partners, and other industry stakeholders.

Investors interested in Liquidia Corporation should closely monitor the company's presentation at the J.P. Morgan Healthcare Conference and consider the potential opportunities and challenges that lie ahead for this promising biopharmaceutical company. With its strong financial performance, innovative product pipeline, and strategic collaborations, Liquidia is well-positioned to continue its growth and create value for shareholders in the years to come.